Legislation – The Health Protection (Coronavirus Restrictions) (No. 5) (Wales) (Amendment) (No. 17) Regulations 2021

“Specific measures applicable to premises where music is provided for dancing or at which specified events are held16A.

(1)

Where regulation 16(1) applies to a person responsible for premises described in paragraph (2), the reasonable measures to be taken by the responsible person under Step 3 of that regulation must include measures to ensure that a person aged 18 or over is only permitted to be present on the premises if the person possesses evidence—

(a)

complying with the requirements in paragraph (6), that the person has completed a course of doses of an authorised vaccine,

(b)

that the person has participated in, or is participating in, a clinical trial, within the meaning of regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 20044, of a vaccine for vaccination against coronavirus carried out in the United Kingdom in accordance with the requirements of those Regulations,

(c)

of a negative result from a qualifying test taken by the person no more than 48 hours before the person enters the premises, or

(d)

of a positive result from a polymerase chain reaction test taken by the person no more than 180 days and no less than 10 days before the person enters the premises.

(2)

The premises referred to in paragraph (1) are—

(a)

premises that meet all of the following conditions—

(i)

the premises are authorised for the sale or supply of alcohol,

(ii)

the premises provide live or recorded music for members of the public or members of the venue to dance, including nightclubs, discotheques and dance halls, and

(iii)

the premises are open at any time between midnight and 5.00 a.m. (however where this condition is met, the requirement in paragraph (1) applies to the premises at any time they are open, subject to paragraph (3)(a) or (e));

(b)

premises at which an event is taking place and more than 10,000 people are in attendance at any time;

(c)

premises at which an event is taking place to any extent indoors, where—

(i)

more than 500 people are in attendance at any time, and

(ii)

not all the persons attending the event are normally seated during the event;

(d)

premises at which an event is taking place outdoors, where—

(i)

more than 4,000 people are in attendance at any time, and

(ii)

not all the persons attending the event are normally seated during the event.

(3)

But paragraph (1) does not apply to premises—

(a)

of a kind described in paragraph (2)(a) at any time when music is not being provided for members of the public or members of the venue to dance;

(b)

at which an event is held outdoors, where—

(i)

a person is not required to obtain a ticket or pay a fee in order to gain entry to the event, and

(ii)

there are two or more points of entry for persons attending the event;

(c)

at which a protest, or picketing carried out in accordance with the Trade Union and Labour Relations (Consolidation) Act 19925, is being held;

(d)

at which a mass participation sporting event is being held outdoors, such as a marathon, cycling race or triathlon;

(e)

used for the celebration of—

(i)

a solemnisation of a marriage, formation of a civil partnership or alternative wedding ceremony, or

(ii)

the life of a deceased person,

at any time when they are used for any of those purposes.

(4)

In paragraph (1) the reference to a person aged 18 or over does not include a person working or providing voluntary services at the premises.

(5)

For the purposes of paragraph (2)(b) to (d), a person working, or providing voluntary services at the event, is not to be treated as being in attendance at the event.

(6)

For the purposes of paragraph (1)(a), the evidence that a person has completed a course of doses of an authorised vaccine must—

(a)

show that—

(i)

the course of doses was administered to the person in the United Kingdom, under the United Kingdom vaccine roll-out overseas, or in a relevant country, and

(ii)

the day on which the person enters the premises is more than 14 days after the day on which the person completed that course of doses;

(b)

in relation to course of doses of vaccines administered in the United Kingdom, be provided to the person by or on behalf of the Government of the United Kingdom, the Scottish Ministers, the Welsh Ministers or a Northern Ireland department (including by means of letter, text message, e-mail, the NHS COVID Pass website6 or the NHS smartphone app developed and operated by the Secretary of State);

(c)

in relation to a course of doses of vaccines administered by a relevant country, be the EU digital COVID certificate or Centers for Disease Control and Prevention vaccination card.

(7)

For the purposes of paragraph (1)(d), where a person has isolated for a period of less than 10 days calculated in accordance with regulation 6(5) or 7(5), the reference to “10 days” is to be treated as a reference to the number of days for which the person was required to isolate.

(8)

For the purposes of paragraph (6)(a), where a person has received a dose of an authorised vaccine in the United Kingdom and a dose of a vaccine under the United Kingdom vaccine roll-out overseas, the person is deemed to have received a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas.

(9)

For the purposes of this regulation—

(a)

a test is a qualifying test if it is capable of detecting the presence of coronavirus, and is—

(i)

a polymerase chain reaction test provided or administered under the National Health Service Act 20067, the National Health Service (Wales) Act 20068, the National Health Service (Scotland) Act 19789, or the Health and Personal Social Services (Northern Ireland) Order 197210, or

(ii)

a lateral flow test, the results of which may be submitted through the NHS public reporting system11.

(b)

a person has completed a course of doses if the person has received the complete course of doses specified—

(i)

in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine, or

(ii)

in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 201212 for the authorised vaccine.

(10)

In this regulation—

(a)

“authorised vaccine” means a medicinal product for vaccination against coronavirus authorised—

(i)

in relation to doses received in the United Kingdom—

(aa)

for supply in the United Kingdom in accordance with a marketing authorisation, or

(bb)

by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 2012;

(ii)

in relation to doses received in a relevant country, for supply in that country following evaluation by the relevant regulator for the country;

(b)

“the licensing authority” has the meaning given in regulation 6(2) of the Human Medicines Regulations 2012;

(c)

“marketing authorisation” means—

(i)

in relation to a vaccine authorised for supply in the United Kingdom or in a member State, has the meaning given in regulation 8(1) of the Human Medicines Regulations 2012;

(ii)

in relation to a vaccine authorised for supply in a relevant country other than a member State, means a marketing authorisation granted by the relevant regulator for the country;

(d)

“relevant country” means a country listed in the first column of the table in paragraph (11);

(e)

“relevant regulator” in relation to a relevant country, means the regulator identified in the corresponding row of the second column of the table in paragraph (11), and a reference to a regulator in that table is a reference to the regulatory authority of that name designated as a Stringent Regulatory Authority by the World Health Organization pursuant to the operation of the COVAX Facility13;

(f)

“United Kingdom vaccine roll-out overseas” means the administration of vaccine against coronavirus to—

(i)

Crown servants (within the meaning given in section 12(1)(a) to (e) of the Official Secrets Act 198914), government contractors (within the meaning given in section 12(2) of the Official Secrets Act 1989) or other personnel posted or based overseas and their dependants under the scheme known as the Foreign, Commonwealth and Development Office staff COVID-19 vaccination programme,

(ii)

residents of the British overseas territories, the Channel Islands and the Isle of Man, as part of a programme agreed in the overseas territory with the United Kingdom government, or

(iii)

military or civilian personnel, government contractors and their dependants at a military posting overseas, including the British overseas territories, the Channel Islands and the Isle of Man, under the vaccination scheme provided or approved by the UK Defence Medical Services.

(11)

The table referred to in the definitions of “relevant country” and “relevant regulator” follows—

Relevant country	Relevant regulator
a member State	European Medicines Agency
Andorra	European Medicines Agency
Iceland	European Medicines Agency
Liechtenstein	European Medicines Agency
Monaco	European Medicines Agency
Norway	European Medicines Agency
San Marino	European Medicines Agency
Switzerland	Swissmedic
the United States of America	United States Food and Drug Administration
Vatican City State	European Medicines Agency”

“Powers relating to offence of possessing false or misleading evidence relating to vaccination or coronavirus test results30A.

Where an enforcement officer has reasonable grounds for suspecting that a person is committing an offence under regulation 40A, the officer may require the person to produce any evidence of a kind described in regulation 16A(1) which the officer suspects is in the person’s possession.”

“Offence of possessing false or misleading evidence relating to vaccination or coronavirus test results40A.

It is an offence for a person (“P”) to possess evidence of a kind described in regulation 16A(1) which P knows is false or misleading.”